OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting

Revised labeling for Purdue Pharma LP’s reformulated OxyContin (oxycodone HCl controlled-release) approved by FDA on April 16 allows the company to market the drug with a claim for reduced abuse by injection and snorting and eliminates the possibility of generic competition based on the original formula.

“In vitro data demonstrate that OxyContin has physicochemical properties expected to make abuse via injection difficult,” labeling says, while data from both the in vitro and clinical studies “indicate that...